A5026072640- Rheumatoid Arthritis Research and Therapies
- Bone health and treatments
- Bone health and osteoporosis research
- Biosimilars and Bioanalytical Methods
- Bone Metabolism and Diseases
- Chronic Lymphocytic Leukemia Research
- Adrenal Hormones and Disorders
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Bone and Joint Diseases
- Drug-Induced Adverse Reactions
- Inflammatory mediators and NSAID effects
- Hip and Femur Fractures
- Musculoskeletal synovial abnormalities and treatments
- Gout, Hyperuricemia, Uric Acid
- Pharmaceutical studies and practices
- Vitamin C and Antioxidants Research
- Paraoxonase enzyme and polymorphisms
- Vitamin D Research Studies
- Musculoskeletal Disorders and Rehabilitation
- Thyroid Cancer Diagnosis and Treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Orthopaedic implants and arthroplasty
- Spondyloarthritis Studies and Treatments
- Salivary Gland Disorders and Functions
Fairfield Medical Center
2023
University of North Carolina Health Care
2023
Georgetown University
2023
Ohio University
2023
University of California, Los Angeles
2007-2023
Robin Medical (United States)
2009-2021
UCLA Health
2011
Anaheim University
1995-2008
American College of Rheumatology
1991
Abt Global (United States)
1991
Abstract Objective RANKL is essential for osteoclast development, activation, and survival. Denosumab a fully human monoclonal IgG2 antibody that binds RANKL, inhibiting its activity. The aim of this multicenter, randomized, double‐blind, placebo‐controlled, phase II study was to evaluate the effects denosumab on structural damage in patients with rheumatoid arthritis (RA) receiving methotrexate treatment. Methods RA received subcutaneous placebo (n = 75), 60 mg 71), or 180 72) injections...
In women with postmenopausal osteoporosis, we investigated the effects of 24 months treatment alendronate (ALN) following 18 abaloparatide (ABL) or placebo (PBO).Women who completed ABL PBO in ACTIVE were eligible to receive up ALN. We evaluated incidence vertebral and nonvertebral fractures changes bone mineral density (BMD) during entire 43-month period from baseline end ACTIVExtend for 24-month extension only.Five hundred fifty-eight ACTIVE's group 581 its (92% completers) enrolled....
Teriparatide (rDNA origin) injection [recombinant human PTH (1–34)] stimulates bone formation, increases mineral density (BMD), and restores architecture integrity. In contrast, bisphosphonates reduce resorption increase BMD. We compared the effects of teriparatide alendronate sodium on BMD, nonvertebral fracture incidence, turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections 40 μg plus oral placebo (n = 73) or 10 mg 73). Median...
Objectives To report results of subgroup analyses bone mineral density (BMD) and turnover markers from a randomised, double-blind, placebo-controlled, phase II study denosumab, an investigational RANKL inhibitor, in patients with rheumatoid arthritis (RA) concurrently receiving treatment bisphosphonates or glucocorticoids. Methods Patients received subcutaneous placebo (n=75), denosumab 60 mg (n=71) 180 (n=72) at baseline 6 months. Assessments included dual x-ray absorptiometry scans the...
Background: Cevimeline hydrochloride is a cholinergic agent with muscarinic agonist activity prominently affecting the M1 and M3 receptors prevalent in exocrine glands.Weevaluatedthesafetyandefficacyofcevimelineinthetreatment of xerostomia patients Sjo ¨gren syndrome.Methods: Seventy-five syndrome associated salivary gland dysfunction were enrolled double-blind, randomized, placebocontrolled trial at 8 university-and office-based outpatient clinical facilities United States.Eligible study...
Periarticular osteoporosis is one of the earliest radiographic signs bone damage in rheumatoid arthritis (RA). Denosumab, an investigational fully human monoclonal antibody that binds to RANKL, inhibits erosion and systemic loss clinical studies patients with RA. In this hand mineral density (BMD) substudy, we investigated effects denosumab on BMD its correlation scores.Patients receiving methotrexate for erosive RA were randomized a 1:1:1 ratio receive subcutaneous placebo, 60 mg, or 180 mg...
A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib diclofenac in patients with rheumatoid arthritis (RA).A total 4086 (mean age 60.8 years) diagnosed RA were enrolled received 90 mg daily (n = 2032) or 75 twice 2054). Use gastroprotective agents low-dose aspirin was allowed. The prespecified primary end point consisted cumulative rate patient discontinuations due clinical laboratory GI adverse experiences (AEs). General also...
ABSTRACT In the randomized, placebo-controlled, double-blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk osteoporotic fracture significantly reduced vertebral, nonvertebral, clinical, and major fractures increased bone mineral density (BMD) versus placebo regardless baseline factors. Women from groups who completed were eligible for ACTIVExtend (NCT01657162), which all enrollees received sequential,...
Glucocorticoids are commonly prescribed medications to treat multiple diseases across many medical specialties. One of the most common yet largely unappreciated side effect glucocorticoid use is increased risk fracture. Many different therapies indicated prevent and this condition; guidelines exist that suggest appropriate both glucocorticoids approved therapy. Nevertheless, 30%-50% patients on long-term therapy sustain a Teriparatide, recombinant human parathyroid hormone (1-34), daily...
Objective Our objective was to evaluate the factors associated with regional variation of rheumatoid arthritis (RA) disease burden in US. Methods In a retrospective cohort analysis Rheumatology Informatics System for Effectiveness (RISE) registry data, seropositivity, RA activity (Clinical Disease Activity Index [CDAI], Routine Assessment Patient Data–version 3 [RAPID3]), socioeconomic status (SES), geographic region, health insurance type, and comorbidity were recorded. An Area Deprivation...
To evaluate changes in bone turnover and mineral density (BMD) patients with rheumatoid arthritis (RA) receiving glucocorticoids, after discontinuation of denosumab for 12 months.We conducted a randomized, double-blind, placebo-controlled, phase II study RA patients. Patients received placebo, 60 mg, or 180 mg every 6 months were followed up an additional discontinuation, during which no loss prevention therapy was instituted. Changes from baseline serum C-terminal telopeptide type I...
ABSTRACT: The distinctions between eosinophilic fasciitis (Shulman's syndrome) and scleroderma may sometimes be unclear. We describe a patient with generalized morphea who also had peripheral blood eosinophilia, fibrosis inflammation of fascia, hyper‐globulinemia, features usually attributed to Shulman's syndrome. latter diagnosis should restricted those patients whose history, clinical laboratory findings, response therapy closely resemble original description. Scleroderma represent...
Abaloparatide increased ultradistal radius bone mineral density (BMD) in the Comparator Trial Vertebral Endpoints (ACTIVE) trial. Over subsequent 24 months ACTIVExtend, BMD gains were maintained with alendronate. Conversely, 1/3 remained stable during ALN treatment ACTIVExtend after decreasing ACTIVE.Abaloparatide (ABL) femoral neck, total hip, and lumbar spine postmenopausal women osteoporosis decreased risk of vertebral nonvertebral fractures ACTIVE. Effects on fracture subsequently...